Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

Clinical Cancer Research 13, 6834-6841, November 15, 2007. doi: 10.1158/1078-0432.CCR-07-0407
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bean, G. R.
Right arrow Articles by Seewaldt, V. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bean, G. R.
Right arrow Articles by Seewaldt, V. L.

Cancer Susceptibility and Prevention

Morphologically Normal-Appearing Mammary Epithelial Cells Obtained from High-Risk Women Exhibit Methylation Silencing of INK4a/ARF

Gregory R. Bean1, Andrew D. Bryson1, Patrick G. Pilie1, Vanessa Goldenberg1, Joseph C. Baker, Jr.1, Catherine Ibarra1, Danielle M.U. Brander1, Carolyn Paisie1, Natalie R. Case1, Mona Gauthier5, Paul A. Reynolds5, Eric Dietze1, Julie Ostrander1, Victoria Scott1, Lee G. Wilke1, Lisa Yee2, Bruce F. Kimler3, Carol J. Fabian3, Carola M. Zalles4, Gloria Broadwater1, Thea D. Tlsty5 and Victoria L. Seewaldt1

Authors' Affiliations: 1 Duke University Medical Center, Durham, North Carolina; 2 The Ohio State University Medical Center, Columbus, Ohio; 3 University of Kansas Medical Center, Kansas City, Kansas; 4 Yale-New Haven Medical Center, New Haven, Connecticut; and 5 University of California at San Francisco Medical Center, San Francisco, California

Requests for reprints: Victoria L. Seewaldt, Box 2628, Duke University Medical Center, Durham, NC 27710. Phone: 919-668-2455; Fax: 919-668-2458; E-mail: seewa001{at}mc.duke.edu.

Purpose: p16(INK4a) has been appreciated as a key regulator of cell cycle progression and senescence. Cultured human mammary epithelial cells that lack p16(INK4a) activity have been shown to exhibit premalignant phenotypes, such as telomeric dysfunction, centrosomal dysfunction, a sustained stress response, and, most recently, a dysregulation of chromatin remodeling and DNA methylation. These data suggest that cells that lack p16(INK4a) activity would be at high risk for breast cancer development and may exhibit an increased frequency of DNA methylation events in early cancer.

Experimental Design: To test this hypothesis, the frequencies of INK4a/ARF promoter hypermethylation, as well as four additional selected loci, were tested in the initial random periareolar fine needle aspiration samples from 86 asymptomatic women at high risk for development of breast cancer, stratified using the Masood cytology index.

Results: INK4a/ARF promoter hypermethylation was observed throughout all early stages of intraepithelial neoplasia and, importantly, in morphologically normal-appearing mammary epithelial cells; 29 of 86 subjects showed INK4a/ARF promoter hypermethylation in at least one breast. Importantly, INK4a/ARF promoter hypermethylation was not associated with atypia, and the frequency of hypermethylation did not increase with increasing Masood cytology score. The frequency of INK4a/ARF promoter hypermethylation was associated with the combined frequency of promoter hypermethylation of retinoic acid receptor-ß2, estrogen receptor-{alpha}, and breast cancer-associated 1 genes (P = 0.001).

Conclusions: Because INK4a/ARF promoter hypermethylation does not increase with age but increases with the frequency of other methylation events, we predict that INK4a/ARF promoter hypermethylation may serve as a marker of global methylation dysregulation.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2007 by the American Association for Cancer Research.